A Phase 2 interventional study of AXS-05 (dextromethorphan-bupropion) in Treatment Resistant Depression and Major Depressive Disorder, sponsored by Axsome Therapeutics, Inc.. Terminated at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.
Sponsored by Axsome Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 35th largest by enrollment of the 181 interventional ones that give a count, is one of 15 that started in 2020, is one of 52 in phase 2, and was the 116th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 181 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 83 across the 22 observational. Of the 119 that completed or were terminated, 70 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 204 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
Eligible subjects must have either completed Study AXS-05-TRD-201 immediately prior to enrollment in this study or meet the DSM-5 criteria for major depressive disorder (MDD) without psychotic features.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AXS-05 (dextromethorphan-bupropion)
\- Titrated to AXS-05 (45 mg dextromethorphan HBr / 105 mg bupropion HCl) twice daily (up to 15 months)
Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05
Time frame: Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.
| Milestone | AXS-05 |
|---|---|
| Started | 181 |
| Completed | 11 |
| Not completed | 170 |
| Withdrew: Study terminated by sponsor | 95 |
| Withdrew: Withdrawal by subject | 20 |
| Withdrew: All other reasons | 55 |
| Participants | AXS-05 |
|---|---|
| Subjects with any TEAEs | 112 |
| Subjects with suspected to be drug-related TEAEs | 65 |
| Subjects with serious TEAEs | 7 |
| Subjects with TEAEs that led to drug withdrawal | 16 |
| Subjects with TEAEs that led to withdrawal from study | 14 |
| Subjects with TEAEs that resulted in death | 0 |
Collected over Duration of participation was up to 15 months. TEAEs were defined as any AE with an onset date in the interval between the first study treatment dosing date and 7 days after the last study treatment dosing date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AXS-05 | 0/181 (0%) | 7/181 (3.9%) | 38/181 (21%) |
| Event | AXS-05 |
|---|---|
| Inappropriate antidiuretic hormone secretionEndocrine disorders | 1/181 |
| CholecystitisHepatobiliary disorders | 1/181 |
| COVID-19 pneumoniaInfections and infestations | 1/181 |
| Coronavirus infectionInfections and infestations | 1/181 |
| Urinary tract infectionInfections and infestations | 1/181 |
| Procedural painInjury, poisoning and procedural complications | 1/181 |
| HyponatraemiaMetabolism and nutrition disorders | 1/181 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/181 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/181 |
| Metabolic encephalopathyNervous system disorders | 1/181 |
| Event | AXS-05 |
|---|---|
| Covid-19Infections and infestations | 15/181 |
| NauseaGastrointestinal disorders | 15/181 |
| HeadacheNervous system disorders | 12/181 |
| Age, Continuous(years) | AXS-05 |
|---|---|
| Mean | 46.6 ± 13.1 |
| Sex: Female, Male(Participants) | AXS-05 |
|---|---|
| Female | 113 |
| Male | 68 |
| Race/Ethnicity, Customized(Participants) | AXS-05 |
|---|---|
| White | 144 |
| Black or African American | 29 |
| Asian | 3 |
| Other | 3 |
| Multiple | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Feb 2022, 16 months.
Results were first posted in Jan 2026, 3 years 11 months after primary completion. A results delay was requested in Mar 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05
Depressive Disorder, Treatment-Resistant →